BofA has upgraded Amylyx ( NASDAQ: AMLX ) to buy based on the potential of the company’s drug avexitide for the treatment of post-bariatric hypoglycemia, or PBH. The investment firm believes avexitide could be the first approved treatment for PBH. It noted that the.
